Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Jafar Sadik Shaik"'
Autor:
Caroline R Perry, Dung Nguyen, Jafar Sadik Shaik, David Gardiner, Etienne Dumont, Courtney Tiffany, Rajendra P. Singh, Mohammad Hossain, Aline Barth, Guoying Tai
Publikováno v:
British Journal of Clinical Pharmacology. 88:416-428
AIMS To develop physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) models to predict effective doses of gepotidacin in paediatrics for the treatment of pneumonic plague (Yersinia pestis). METHODS A gepotidacin PBPK mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eccd104e7e14ea0c2a0863cd9748aa10
https://doi.org/10.1111/bcp.14996
https://doi.org/10.1111/bcp.14996
Autor:
Susan Swindells, Jafar Sadik Shaik, Scott Letendre, Herta Crauwels, Kenneth Sutton, Christopher J Bettacchi, Jerome deVente, Debbie Hagins, Ronald D'Amico, Parul Patel, Anthony Mills, Franco Felizarta, Susan L. Ford, Yu Lou
Publikováno v:
The Journal of antimicrobial chemotherapy, vol 75, iss 3
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy
Background Long-acting (LA) formulations of cabotegravir, an HIV integrase inhibitor, and rilpivirine, an NNRTI, are in development as monthly or 2 monthly intramuscular (IM) injections for maintenance of virological suppression. Objectives To evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::607640a08c19a6855de50558c93adb7e
https://doi.org/10.1093/jac/dkz504
https://doi.org/10.1093/jac/dkz504
Autor:
William Spreen, Yu Lou, Susan L. Ford, Jafar Sadik Shaik, Parul Patel, Christine Trezza, Zhiping Zhang, Allan R Tenorio, Kalpana Bakshi
Publikováno v:
Clinical Pharmacology in Drug Development
Cabotegravir is an investigational integrase inhibitor in development for the treatment and pre‐exposure prophylaxis of HIV‐1 infection. Liver disease is a major cause of morbidity and mortality in HIV‐infected individuals and can impact the ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d96d97fa9d243ce4da38703cb911027
https://doi.org/10.1002/cpdd.655
https://doi.org/10.1002/cpdd.655
Autor:
Trevor Shreeves, Nancy Skoura, Shashidhar Joshi, Ann M. Buchanan, Jafar Sadik Shaik, Linda N. Casillas, Rajendra P. Singh
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes (1999)
Supplemental Digital Content is Available in the Text.
Background: The fixed-dose combination (FDC) tablet formulation of abacavir/dolutegravir/lamivudine is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighin
Background: The fixed-dose combination (FDC) tablet formulation of abacavir/dolutegravir/lamivudine is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::350249f81c8f84800780bbe9c1a32650
https://doi.org/10.1097/qai.0000000000001859
https://doi.org/10.1097/qai.0000000000001859
Autor:
Kelong Han, Kalpana Bakshi, William Spreen, Yu Lou, David A. Margolis, Craig W. Hendrix, Sharon A. Riddler, Edward J. Fuchs, Ronald D'Amico, Jafar Sadik Shaik, Susan L. Ford, Parul Patel, Stacey Edick, Ethel D. Weld, Mark A. Marzinke
Publikováno v:
British journal of clinical pharmacology. 88(4)
Aims Cabotegravir is an integrase strand transfer inhibitor in clinical development as long-acting (LA) injectable HIV preexposure prophylaxis. Methods This phase I study assessed pharmacokinetics of cabotegravir in plasma and anatomical sites associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bd3854b0e21f12904c3e4aa98f12d3d
https://pubmed.ncbi.nlm.nih.gov/34240467
https://pubmed.ncbi.nlm.nih.gov/34240467
Autor:
Jafar Sadik Shaik, Valeriu Damian, Katarzyna J. Macura, Susan L. Ford, Paul Galette, Kalpana Bakshi, Craig W. Hendrix, Michael A. Jacobs, Meiyappan Solaiyappan, Robert L. Janiczek, Sarah Lee, Manish Gupta, William Spreen, Beat M. Jucker, Edward J. Fuchs, Kelong Han, Ethel D. Weld, Parul Patel, Ronald D'Amico, David A. Margolis
Publikováno v:
British journal of clinical pharmacology. 88(4)
Aim Cabotegravir long-acting (LA) intramuscular (IM) injection is being investigated for HIV preexposure prophylaxis due to its potent antiretroviral activity and infrequent dosing requirement. A subset of healthy adult volunteers participating in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::365905f764b24bf4cc0ca8430b97f6df
https://pubmed.ncbi.nlm.nih.gov/35350084
https://pubmed.ncbi.nlm.nih.gov/35350084
Autor:
Jafar Sadik Shaik, Robert S. B. Clark, Patrick M. Kochanek, Dana L. Tudorascu, Samuel M. Poloyac, Mioara D. Manole, Henry Alexander
Publikováno v:
Journal of Cerebral Blood Flow & Metabolism. 35:1757-1763
Vasoconstrictive and vasodilatory eicosanoids generated after cardiac arrest (CA) may contribute to cerebral vasomotor disturbances and neurodegeneration. We evaluated the balance of vasodilator/vasoconstrictor eicosanoids produced by cytochrome P450
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6e54e223e8661e4c81ff49b60f30dd9
https://doi.org/10.1038/jcbfm.2015.117
https://doi.org/10.1038/jcbfm.2015.117
Publikováno v:
Journal of Chromatography B. :207-216
The metabolites of arachidonic acid (AA) produced from the cyclooxygenase (COX) pathway, collectively termed as prostanoids, and from the CYP 450 pathway, eicosanoids, have been implicated in various neuro-degenerative and neuroinflammatory diseases.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a774f5a031faac5839f16ae02dd17c94
https://doi.org/10.1016/j.jchromb.2013.11.041
https://doi.org/10.1016/j.jchromb.2013.11.041
Autor:
Jafar Sadik Shaik, Christine Trezza, Zhiping Zhang, William Spreen, Yu Lou, Kalpana Bakshi, Parul Patel, Susan L. Ford, Allan R Tenorio
Publikováno v:
Open Forum Infectious Diseases
Background Cabotegravir (CAB) is an integrase inhibitor in phase 3 clinical trials for the treatment and prevention of HIV. CAB undergoes hepatic metabolism primarily via UGT1A1; thus hepatic impairment has the potential to affect CAB exposure. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0535a4685dcf2bf3e2dbb09bc9c07adb
http://europepmc.org/articles/PMC5631467
http://europepmc.org/articles/PMC5631467
Autor:
J. Alyce Bradbury, Fred B. Lih, Hong Li, Kenneth B. Tomer, Samantha L. Hoopes, Craig R. Lee, Darryl C. Zeldin, Michal L. Schwartzman, Jennifer Cheng, John R. Falck, Jafar Sadik Shaik, Laura M. DeGraff, Samuel M. Poloyac, Gordon P. Flake, Matthew L. Edin, Joan P. Graves, Victor Garcia
Publikováno v:
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 28(7)
Cytochrome P450 (CYP) 4A and 4F enzymes metabolize arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE). Although CYP4A-derived 20-HETE is known to have prohypertensive and proangiogenic properties, the effects of CYP4F-derived metabolites a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0ceb82ae2c633746a0debaa0a3eb661
https://pubmed.ncbi.nlm.nih.gov/24668751
https://pubmed.ncbi.nlm.nih.gov/24668751